1. First Visit: Break the Ice and Build Trust First, Then Anchor Clinical Needs
During the first visit, the physician is unfamiliar with the rep. The topic should first show that "you understand their profession" and avoid jumping directly into the product. The core logic is: focus on the physician's professional identity -> introduce real clinical problems -> naturally connect to product value.
1. Start From the Physician's Professional Achievements to Close the Distance
Before the visit, use the hospital website, academic databases, and conference materials to understand the physician's research direction, such as diabetic nephropathy or lung cancer targeted therapy, recent papers, or projects, then use that as the opening topic.
- Example 1 for a physician with papers: "Director Li, I read your paper in the Chinese Journal of Endocrinology and Metabolism on the effect of XX drug on islet function in type 2 diabetes patients. The section discussing management challenges in XX complications resonated strongly with our team. May I ask how you handle this type of patient in clinical practice?"
- Example 2 for a physician involved in academic projects: "Professor Wang, I heard you are leading a survey on EGFR mutation rates among lung cancer patients in the XX region. This project is very meaningful for clinical medication guidance. We have also been paying attention to follow-up treatment plans for these patients and would like to understand which unmet needs you have found in the survey."
Advantage: this shows the rep has done their homework rather than visiting blindly. The topic focuses on the physician's professional field and is more likely to create resonance.
2. Start From Common Clinical Pain Points in the Department to Connect With Real Needs
Based on the product's indication, identify diagnosis and treatment challenges physicians often face, such as controlling drug side effects, poor patient adherence, or outcomes below expectations. Use questions to trigger discussion instead of directly giving answers.
- Example 1 for cardiologists, with an antihypertensive product: "Director Zhang, when you see hypertensive patients with coronary heart disease, do you worry about the effect of antihypertensive drugs on heart rate? Many cooperating physicians told us these patients require frequent heart rate monitoring after medication. What experience do you have in managing this?"
- Example 2 for oncologists, with a chemotherapy adjuvant drug: "Dr. Liu, advanced gastric cancer patients often experience severe nausea and vomiting after chemotherapy, and many interrupt treatment because of this. In clinical practice, beyond standard antiemetic plans, what other methods do you consider to improve patient tolerance?"
Advantage: the topic directly addresses physicians' daily work troubles and can stimulate willingness to communicate. Later, the rep can naturally transition to relevant clinical data on how the product helps address this type of pain point, rather than pushing hard.
2. Follow-Up Visits: Use Academic Value Follow-Up to Deepen Trust
The key to follow-up visits is continuing the previous topic and providing valuable academic support, helping physicians feel the rep is an academic partner rather than a simple salesperson. Topics can revolve around data supplements, clinical cases, and industry updates.
1. Follow Up on Unresolved Clinical Questions and Provide Academic Materials
If the physician mentioned a pain point during the first visit, such as elevated liver enzymes after medication, bring targeted materials during the follow-up, such as liver safety study data, expert consensus interpretation, or medication cases for similar patients.
- Example 1, supplementing data: "Director Li, last time you mentioned concern about the impact of XX drug on renal function. We recently organized a subgroup analysis from a multicenter study. For patients with eGFR 30-60, after 12 weeks using our product, the abnormal renal function indicator rate was only 2.3%, 50% lower than similar drugs. I would like to share this data report with you."
- Example 2, sharing a case: "Dr. Wang, last time you mentioned a patient with XX disease in your department whose response remained poor after two regimens. We recently received a case from a Shanghai hospital with a similar situation. After switching to our product combined with XX regimen, symptoms improved significantly within four weeks. Would you like to look at the case details?"
Advantage: this shows the rep's follow-up capability, and the materials directly support the physician's clinical decisions, creating strong value.
2. Discuss Academic Updates to Trigger Deeper Conversation
Based on the physician's field, share the latest guideline updates, key views from authoritative conferences such as ESC, ASCO, or Chinese Medical Association branch meetings, or frontier research in the industry, and naturally incorporate the product's advantages.
- Example 1, guideline update: "Director Zhang, this year's Chinese Type 2 Diabetes Prevention and Treatment Guideline was just updated and mentions prioritizing XX-class drugs as second-line therapy. Do you think this adjustment will significantly affect clinical medication? Our product fits the guideline's cardiovascular protection direction, and I would like to hear your interpretation."
- Example 2, academic meeting: "Professor Liu, at ASCO last week, a team released research on a new target in XX cancer. Did you follow it? Our product's mechanism happens to relate to this target, and there may be potential for combination therapy later. Do you think this direction is worth exploring?"
Advantage: the topic focuses on academic frontiers and matches physicians' need for professional development, while connecting the product with industry trends without hard selling.
3. Discuss Practical Patient Management Topics That Fit Clinical Scenarios
Besides diagnosis and treatment plans, physicians also care about long-term patient management, such as medication adherence and follow-up efficiency. You can share patient education materials or convenient monitoring tools. These topics are practical and easy to implement.
- Example: "Dr. Chen, during hypertension follow-ups in your department, do you find patients record blood pressure irregularly? We created a home blood pressure monitoring handbook with clear recording tables and notes. Patients found it convenient. I brought a few copies today, and you can try them with patients in your department."
Advantage: the topic does not involve product selling, but it helps physicians solve small practical problems at work and indirectly increases trust in the rep.
3. Pitfall Guide: Topics That Must Not Be Touched
Compliance is the bottom line of academic visits. The following topics must be strictly avoided to prevent crossing regulatory red lines:
- Absolute claims, such as "our product is the best" or "it can cure XX disease." All views should be based on product instructions and clinical research data, using phrases like "research shows" or "data indicate" instead of absolute conclusions.
- Private topics unrelated to academics, such as physician income, family situation, or gossip. Maintain the boundary of professional communication.
- Benefit-related topics, such as prescription-volume rebates, gift cards, travel, or sponsoring private consumption. All cooperation must stay within a compliance framework, such as academic meeting sponsorship or patient education project support.
- Asking about prescription volume, such as "how many prescriptions of our product do you write each month." Compliance requirements prohibit pharma reps from counting or interfering with physician prescribing behavior.
4. Key Skill: Make the Topic Interactive, Not One-Way Output
A good academic visit is not about the rep speaking more, but about deeper conversation. The core is ask more, listen more, and lecture less:
- Use fewer statements and more questions. For example, instead of saying "our product has good safety," ask "when choosing XX drugs in clinical practice, which safety indicators do you care about most? Our product's performance in this area may offer a useful reference."
- Respond seriously to the physician's views. If the physician says, "your data sample size is too small," do not argue. Say, "That is a very important point. We will continue following larger-sample studies, and I would also like to ask what sample size you think would make study conclusions more clinically useful." Use interaction to deepen the discussion.
A more convenient method is to use tools that organize HCP data and talking points for you, such as MeDomino's HCP Navigator product. Detailed information is available on the MeDomino website.
Related Q&A
Q1: What is the primary dimension to consider when screening target HCPs?
A1: The first priority is professional fit and compliance qualification. Professional fit should focus on consistency between the physician's department or subspecialty and the drug indication, such as oncology drugs matching oncology and antidiabetic drugs matching endocrinology, as well as target patient volume potential. Compliance qualification should verify normal practice status and prescribing or research qualifications. This is the foundation for avoiding resource mismatch and compliance risk.
Q2: What capabilities should be emphasized when screening HCPs suitable for clinical trials?
A2: Focus on three capability types: 1. Research qualification: confirm whether the physician's department has GCP qualification, such as Phase III oncology trial qualification. 2. Research experience: review past projects, such as whether the physician led Phase II trials of similar drugs, and trial completion rate to avoid those with high project delay rates. 3. Patient enrollment capability: check the number of patients meeting inclusion and exclusion criteria seen each month to ensure efficient trial progress.
Q3: How does HCP screening for grassroots markets, such as community hospitals, differ from tertiary hospitals?
A3: The main difference is screening focus. 1. Capability dimension: grassroots screening prioritizes common disease diagnosis and treatment experience, such as whether community physicians are skilled in hypertension or diabetes management, and patient stickiness such as follow-up rate and satisfaction, rather than academic output. 2. Resource fit: prioritize physicians willing to participate in patient education, such as community health lecture speakers, rather than academic KOLs.
Q4: How do screening criteria differ between KOLs and KOCs, or grassroots opinion leaders?
A4: The core difference lies in influence scope and capability focus. 1. KOL screening looks at national or regional academic voice, such as whether the physician speaks at ASCO or Chinese Medical Association annual meetings, and prioritizes department heads and guideline developers. 2. KOC screening looks at grassroots reach, such as whether nearby community physicians often consult them on cases and whether they have speaker records at local small meetings, prioritizing grassroots hospital department heads and county hospital backbones.
Q5: Does a screened HCP list need dynamic adjustment? What should adjustments be based on?
A5: Dynamic adjustment is required. Bases include: 1. Capability changes, such as new high-value papers or new clinical trial experience. 2. Behavior changes, such as interaction frequency; if the physician has not joined academic activities for six months, cooperation willingness needs reassessment. 3. Compliance changes: regularly check medical insurance bureau and drug administration blacklists. If a physician has new violation records, cooperation should stop immediately.
